Glenmede Trust CO Na Akebia Therapeutics, Inc. Transaction History

Glenmede Trust CO Na

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$2.22 - $3.78 $12,107 - $20,616	-5,454 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$2.39 - $13.08 $7,334 - $40,142	3,069 Added 128.68%	5,454 $13,000
Q2 2020 Aug 14, 2020	SELL	$6.67 - $13.58 $14,147 - $28,803	-2,121 Reduced 47.07%	2,385 $32,000
Q4 2019 Feb 12, 2020	SELL	$3.16 - $6.73 $4,237 - $9,024	-1,341 Reduced 22.93%	4,506 $28,000
Q3 2019 Nov 14, 2019	SELL	$3.55 - $5.4 $1,288 - $1,960	-363 Reduced 5.85%	5,847 $22,000
Q1 2019 May 14, 2019	BUY	$5.41 - $8.73 $9,218 - $14,875	1,704 Added 37.82%	6,210 $49,000
Q4 2018 Feb 14, 2019	BUY	$5.39 - $9.15 $24,287 - $41,229	4,506 New	4,506 $24,000

121

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $386M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.